Targeting HER 1 and 2 in breast cancer with lapatinib

被引：1

作者：

Higa, Gerald M. ^{[1
]}

机构：

[1] West Virginia Univ, Mary Babb Randolph Canc Ctr, Sch Pharm, Morgantown, WV 26506 USA

来源：

ONCOLOGY REVIEWS | 2008年 / 2卷 / 01期

关键词：

EGFR; HER1; HER2; HER3; Lapatinib;

D O I：

10.1007/s12156-008-0052-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Numerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and potentially curable, disease. Until recently, development of resistance to trastuzumab left patients with no therapeutic option other than specifically targeted HER2. This paper provides an in-depth review of lapatinib, a dual HER kinase inhibitor, as well as some insight into three HER family members, in breast cancer.

引用

页码：21 / 28

页数：8

共 61 条

[1]

ALIMANDI M, 1995, ONCOGENE, V10, P1813

[2] Increased risk of brain metastases in patients with HER2/neu-positive breast carcinoma [J].

Altaha, R ;

Crowell, E ;

Hobbs, G ;

Higa, G ;

Abraham, J .

CANCER, 2005, 103 (03) :442-443

[3]

Anido J, 2003, CLIN CANCER RES, V9, P1274

[4]

[Anonymous], 2003, Clin Adv Hematol Oncol, V1, P237

[5] Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study [J].

Bartsch, R ;

Wenzel, C ;

Hussian, D ;

Pluschnig, U ;

Sevelda, U ;

Koestler, W ;

Altorjai, G ;

Locker, GJ ;

Mader, R ;

Zielinski, CC ;

Steger, GG .

BMC CANCER, 2006, 6 (1)

[6] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].

Baselga, J ;

Albanell, J ;

Ruiz, A ;

Lluch, A ;

Gascón, P ;

Guillém, V ;

González, S ;

Sauleda, S ;

Marimón, I ;

Tabernero, JM ;

Koehler, MT ;

Rojo, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333

[7]

Baulida J, 1996, J BIOL CHEM, V271, P5251

[8] Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects [J].

Bence, AK ;

Anderson, EB ;

Halepota, MA ;

Doukas, MA ;

DeSimone, PA ;

Davis, GA ;

Smith, DA ;

Koch, KM ;

Stead, AG ;

Mangum, S ;

Bowen, CJ ;

Spector, NL ;

Hsieh, S ;

Adams, VR .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (01) :39-49

[9] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[10] Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib [J].

Burris, HA .

ONCOLOGIST, 2004, 9 :10-15

← 1 2 3 4 5 6 7 →